BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 37928286)

  • 1. Durable response to pembrolizumab in microsatellite instability-high advanced adrenocortical carcinoma.
    Senda M; Hashimoto K; Shindo T; Kobayashi K; Tanaka T; Masumori N
    IJU Case Rep; 2023 Nov; 6(6):382-385. PubMed ID: 37928286
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Response to Immunotherapy in Combination With Mitotane in Patients With Metastatic Adrenocortical Cancer.
    Head L; Kiseljak-Vassiliades K; Clark TJ; Somerset H; King J; Raeburn C; Albuja-Cruz M; Weyant M; Cleveland J; Wierman ME; Leong S
    J Endocr Soc; 2019 Dec; 3(12):2295-2304. PubMed ID: 31745526
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term survival of a patient with refractory advanced adrenocortical carcinoma after combination chemotherapy with paclitaxel and carboplatin plus mitotane.
    Kobayakawa Y; Hamamoto S; Kamisawa H; Okada S; Taguchi K; Naiki T; Okada A; Tozawa K; Yasui T
    IJU Case Rep; 2022 Jul; 5(4):288-292. PubMed ID: 35795129
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Complete Radiological Response of Recurrent Metastatic Adrenocortical Carcinoma to Pembrolizumab and Mitotane.
    Alam W; Bouferraa Y; Haibe Y; Shamseddine A
    Clin Med Insights Oncol; 2021; 15():11795549211007682. PubMed ID: 33889043
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase II trial of combination chemotherapy and surgical resection for the treatment of metastatic adrenocortical carcinoma: continuous infusion doxorubicin, vincristine, and etoposide with daily mitotane as a P-glycoprotein antagonist.
    Abraham J; Bakke S; Rutt A; Meadows B; Merino M; Alexander R; Schrump D; Bartlett D; Choyke P; Robey R; Hung E; Steinberg SM; Bates S; Fojo T
    Cancer; 2002 May; 94(9):2333-43. PubMed ID: 12015757
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination chemotherapy in advanced adrenocortical carcinoma.
    Fassnacht M; Terzolo M; Allolio B; Baudin E; Haak H; Berruti A; Welin S; Schade-Brittinger C; Lacroix A; Jarzab B; Sorbye H; Torpy DJ; Stepan V; Schteingart DE; Arlt W; Kroiss M; Leboulleux S; Sperone P; Sundin A; Hermsen I; Hahner S; Willenberg HS; Tabarin A; Quinkler M; de la Fouchardière C; Schlumberger M; Mantero F; Weismann D; Beuschlein F; Gelderblom H; Wilmink H; Sender M; Edgerly M; Kenn W; Fojo T; Müller HH; Skogseid B;
    N Engl J Med; 2012 Jun; 366(23):2189-97. PubMed ID: 22551107
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II evaluation of cisplatin and etoposide followed by mitotane at disease progression in patients with locally advanced or metastatic adrenocortical carcinoma: a Southwest Oncology Group Study.
    Williamson SK; Lew D; Miller GJ; Balcerzak SP; Baker LH; Crawford ED
    Cancer; 2000 Mar; 88(5):1159-65. PubMed ID: 10699907
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Case report: Remarkable response to a novel combination of mitotane, etoposide, paraplatin, and sintilimab in a patient with metastatic adrenocortical carcinoma.
    Weng Y; Wang L; Wang XY; Fan XX; Yan L; Li ZH; Zhang SL
    Front Endocrinol (Lausanne); 2023; 14():1115893. PubMed ID: 37745701
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Three Cases of Advanced or Recurrent Adrenocortical Carcinoma Patients Treated with Etoposide, Doxorubicin and Cisplatin plus Mitotane].
    Sasaki S
    Gan To Kagaku Ryoho; 2018 Jan; 45(1):67-70. PubMed ID: 29362311
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advanced adrenocortical carcinoma successfully treated with gemcitabine plus capecitabine as second-line chemotherapy.
    Yamamoto A; Nakai Y; Oka T; Kanaki T; Yamamoto Y; Nagahara A; Nakayama M; Kakimoto KI; Nishimura K
    IJU Case Rep; 2020 Nov; 3(6):270-273. PubMed ID: 33163922
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mitotane associated with cisplatin, etoposide, and doxorubicin in advanced childhood adrenocortical carcinoma: mitotane monitoring and tumor regression.
    Zancanella P; Pianovski MA; Oliveira BH; Ferman S; Piovezan GC; Lichtvan LL; Voss SZ; Stinghen ST; Callefe LG; Parise GA; Santana MH; Figueiredo BC
    J Pediatr Hematol Oncol; 2006 Aug; 28(8):513-24. PubMed ID: 16912591
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mitotane associated with etoposide, doxorubicin, and cisplatin in the treatment of advanced adrenocortical carcinoma. Italian Group for the Study of Adrenal Cancer.
    Berruti A; Terzolo M; Pia A; Angeli A; Dogliotti L
    Cancer; 1998 Nov; 83(10):2194-200. PubMed ID: 9827725
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical management and outcomes associated with etoposide, doxorubicin, and cisplatin plus mitotane treatment in metastatic adrenocortical carcinoma: a single institute experience.
    Uchihara M; Tanioka M; Kojima Y; Nishikawa T; Sudo K; Shimoi T; Noguchi E; Maeshima AM; Yonemori K
    Int J Clin Oncol; 2021 Dec; 26(12):2275-2281. PubMed ID: 34468885
    [TBL] [Abstract][Full Text] [Related]  

  • 14. European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors.
    Fassnacht M; Dekkers OM; Else T; Baudin E; Berruti A; de Krijger R; Haak HR; Mihai R; Assie G; Terzolo M
    Eur J Endocrinol; 2018 Oct; 179(4):G1-G46. PubMed ID: 30299884
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Favorable response of metastatic adrenocortical carcinoma to etoposide, adriamycin and cisplatin (EAP) chemotherapy. Report of two cases.
    Berruti A; Terzolo M; Paccotti P; Veglio F; Pia A; Dogliotti L; Angeli A
    Tumori; 1992 Oct; 78(5):345-8. PubMed ID: 1494808
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adrenocortical carcinoma.
    van Ditzhuijsen CI; van de Weijer R; Haak HR
    Neth J Med; 2007 Feb; 65(2):55-60. PubMed ID: 17379929
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [A Case Report of a Patient with Metastatic Adrenocortical Carcinoma who Received the Combination Etoposide, Doxorubicin, Cisplatin, and Mitotane Therapy and Achieved Remission].
    Ueda S; Nakane K; Namiki S; Takeuchi Y; Kawase M; Takeuchi S; Kawase K; Nakai C; Kato D; Takai M; Iinuma K; Tsuchiya T; Miyazaki T; Koie T
    Hinyokika Kiyo; 2022 May; 68(5):139-143. PubMed ID: 35748231
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long response duration to pembrolizumab in metastatic, castration-resistant prostate cancer with microsatellite instability-high and neuroendocrine differentiation: A case report.
    Yoshida T; Yaegashi H; Toriumi R; Kadomoto S; Iwamoto H; Izumi K; Kadono Y; Ikeda H; Mizokami A
    Front Oncol; 2022; 12():912490. PubMed ID: 36185251
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advanced Adrenocortical Carcinoma: Current Perspectives on Medical Treatment.
    Araújo AN; Bugalho MJ
    Horm Metab Res; 2021 May; 53(5):285-292. PubMed ID: 33962475
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rapid Response to Pembrolizumab in a Chemo-Refractory Testicular Germ Cell Cancer with Microsatellite Instability-High.
    Kawai K; Tawada A; Onozawa M; Inoue T; Sakurai H; Mori I; Takiguchi Y; Miyazaki J
    Onco Targets Ther; 2021; 14():4853-4858. PubMed ID: 34584425
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.